Latest News, Newsletter

webinar series episode 16

Radiopharmaceuticals for Pheochromocytoma Paraganglioma
special thanks to progenics for making this webinar series possible through an educational grant.

The information presented on this webinar is for educational purposes only and should not substitute the advice of your doctor(s) and medical team because they have in-depth knowledge of your medical history and current situation.

Download slides here.

See list of questions and video timing below.

Q1 at 52:45: Are either treatments an option for bladder paraganglioma?

Q2 at 54:10: Can you talk about PRRT and radiosensitizing chemo used together?

Q3 at 55:58: Can pheochromocytoma metastasis be secreting and have uptake of MIBG then later on after growing not secrete?

Q4 at 57:29: How often can you have Lutathera? I had it a few years ago, can it be repeated?

Q5 at 1:00:20: How often is Lutathera used in the US? Is it used more often for pheo in Europe?

Q6 at 1:01:59: What medications are contraindicated with Azedra?

Q7 at 1:03:15: Can you fly right after receiving these treatments?

Q8 at 1:06:03: What are the long-term side effects of both?

Q9 at 1:09:09: What radiotherapy type would be best for unresectable bilateral glomus vagale and bilateral carotid body paraganglioma to minimize nerve damage?

Q10 at 1:10:39: After Azedra treatment when should another scan be done to see tumor progression?

Q11 at 1:13:15: Are there any pain management options with metastatic pheo when there is a lot of pain after the first Azedra treatment?

Q12 at 1:14:50: Is there a way to protect the salivary gland the way the thyroid is protected with iron and the kidneys are protected with amino acids?